Aromatase Inhibitors Class Overview Monograph

Mechanism of Action and Classification

Aromatase inhibitors suppress estrogen biosynthesis by targeting CYP19A1, the enzyme that converts androgens (testosterone and androstenedione) into estrogens (estradiol and estrone). In postmenopausal women, adipose tissue, skin, and muscle become the principal sites of estrogen production after ovarian failure, making peripheral aromatase the rate-limiting step in estrogen supply.

Nonsteroidal (Type II) Inhibitors

Anastrozole and letrozole are triazole derivatives that bind reversibly to the heme group of the aromatase enzyme. Letrozole achieves slightly greater estradiol suppression than anastrozole in head-to-head pharmacodynamic studies. A randomized crossover trial (N=12) published in the Journal of Clinical Oncology demonstrated that letrozole suppressed plasma estrone sulfate by 98.4% compared with 95.2% for anastrozole 1. Both agents are selective for CYP19A1, with no clinically meaningful effect on cortisol or aldosterone at standard doses 2.

Steroidal (Type I) Inhibitor

Exemestane is an androstenedione analogue that binds irreversibly to the aromatase active site, functioning as a suicide inhibitor. Because it permanently inactivates each enzyme molecule, estrogen suppression persists until new aromatase protein is synthesized. Exemestane has mild androgenic activity, which may partially offset AI-related bone loss and lipid deterioration 3. This distinction carries practical weight when switching agents after adverse events.

Clinical Indications

AIs are first-line endocrine therapy for postmenopausal women with HR+ breast cancer. They are not indicated as monotherapy in premenopausal women unless combined with ovarian function suppression (OFS).

Adjuvant Breast Cancer

The ATAC trial (Arimidex, Tamoxifen, Alone or in Combination; N=9,366) established anastrozole as superior to tamoxifen for disease-free survival (DFS) in postmenopausal HR+ early breast cancer. At 10-year follow-up, anastrozole reduced recurrence by 26% (HR 0.74, 95% CI 0.64 to 0.87) 4. The BIG 1-98 trial (N=8,010) showed letrozole also improved DFS over tamoxifen monotherapy (HR 0.82, P=0.007) 5.

For extended adjuvant therapy, the MA.17 trial (N=5,187) demonstrated that letrozole after 5 years of tamoxifen reduced the risk of recurrence by 42% (HR 0.58, P<0.001) 6. Current ASCO guidelines recommend a total of 5 to 10 years of endocrine therapy, with the decision to extend based on individual recurrence risk 7.

Metastatic Breast Cancer

In the advanced setting, letrozole demonstrated superior time to progression versus tamoxifen (9.4 months vs. 6.0 months; P<0.001) as first-line therapy in the P025 trial (N=907) 8. AIs are now typically combined with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) as standard first-line treatment for HR+/HER2-negative metastatic disease.

Off-Label Use in Men

In men receiving testosterone replacement therapy, AIs are prescribed off-label to control estradiol levels when aromatization causes symptomatic gynecomastia or when estradiol exceeds 40 to 50 pg/mL. Anastrozole 0.5 to 1 mg two to three times per week or letrozole 2.5 mg two to three times per week are the most common regimens. A retrospective cohort study (N=69 hypogonadal men) found that anastrozole 1 mg daily increased testosterone by 62% while reducing estradiol by 50% over 12 months 9. The Endocrine Society Clinical Practice Guideline on testosterone therapy notes that AIs may be considered for estradiol management in men on TRT, though long-term safety data in this population remain limited 10.

Exemestane is used less commonly in men. Its mild androgenic metabolite (17-hydroexemestane) has theoretical advantages for male bone preservation, but no controlled trial has confirmed this benefit in TRT-treated populations.

Pharmacokinetics and Dosing

All three agents are orally administered with high bioavailability. Exemestane absorption increases approximately 40% when taken with a high-fat meal, so prescribing information recommends administration after food 3.

Comparative Pharmacokinetic Parameters

| Parameter | Anastrozole | Letrozole | Exemestane | |---|---|---|---| | Bioavailability | ~83% (fasting) | ~99.9% | ~42% (fasting) | | Half-life | 40 to 50 h | 48 h (~2 days) | 24 h | | Metabolism | Hepatic (CYP3A4, glucuronidation) | CYP3A4, CYP2A6 | CYP3A4 (primary) | | Steady state | 7 days | 2 to 6 weeks | 7 days | | Standard dose | 1 mg once daily | 2.5 mg once daily | 25 mg once daily (with food) | | Estradiol suppression | ~97% | ~>99% | ~92% |

Dose adjustments are not required for mild-to-moderate renal impairment. Letrozole and anastrozole should be used with caution in severe hepatic impairment (Child-Pugh C), where clearance is reduced 2.

Adverse Effects

The safety profile of AIs reflects the consequences of profound estrogen depletion. Musculoskeletal symptoms are the most common reason for treatment discontinuation.

Musculoskeletal Toxicity

Arthralgia and myalgia affect 20 to 35% of AI-treated patients. In the ATAC trial, arthralgia was reported in 35.6% of anastrozole-treated women vs. 29.4% with tamoxifen 4. Joint stiffness tends to peak in the first 6 months and may improve over time. Switching from a nonsteroidal to a steroidal AI (or vice versa) allows approximately 40 to 70% of patients to continue therapy 11.

Bone Mineral Density Loss

Estrogen deprivation accelerates osteoclast activity. The ATAC bone substudy documented a mean lumbar spine BMD decrease of 6.08% over 5 years with anastrozole vs. 2.77% with tamoxifen 12. The American Society of Clinical Oncology (ASCO) recommends baseline DEXA scanning before or at the start of AI therapy, with repeat imaging at 1 to 2 year intervals 7. Bisphosphonates (zoledronic acid) or denosumab should be initiated when T-scores fall below -2.0 or when clinical fracture risk is high.

Cardiovascular and Metabolic Effects

AIs lack the cardioprotective estrogenic effects of tamoxifen. Long-term follow-up of BIG 1-98 showed a non-significant trend toward increased cardiovascular events with letrozole (4.1% vs. 3.6% with tamoxifen) 5. Exemestane may have a more favorable lipid profile than nonsteroidal AIs; the IES trial (N=4,724) found no significant lipid deterioration with exemestane after switching from tamoxifen 13.

Other Adverse Effects

Hot flashes occur in 12 to 36% of patients. Headache is more common with letrozole. Vaginal dryness increases with all AIs relative to tamoxifen. Rare hepatotoxicity has been reported with anastrozole, prompting monitoring of hepatic transaminases 2. Carpal tunnel syndrome is a recognized but underreported class effect, affecting roughly 2 to 4% of treated patients.

Drug Interactions

Anastrozole and letrozole are metabolized through CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) can raise AI plasma levels, though dose adjustments are not typically required due to the wide therapeutic index. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) may reduce AI efficacy.

Tamoxifen Co-Administration

The ATAC trial included a combination arm (anastrozole plus tamoxifen) that showed no benefit over tamoxifen alone and was discontinued. Tamoxifen reduced anastrozole plasma concentrations by 27%, likely through CYP3A4 induction 4. Concurrent use is not recommended.

Estrogen-Containing Therapies

Any exogenous estrogen (oral contraceptives, systemic HRT, topical estradiol) can negate the pharmacologic effect of AIs. This interaction is absolute. Patients must discontinue estrogen-containing products before starting AI therapy.

Monitoring Recommendations

A structured monitoring plan reduces avoidable morbidity during AI treatment.

Baseline Assessments

Before initiating therapy: DEXA scan (lumbar spine and hip), fasting lipid panel, hepatic function tests, and serum 25-hydroxyvitamin D. Vitamin D deficiency should be corrected before starting AI therapy. The National Osteoporosis Foundation recommends maintaining 25(OH)D levels at 30 ng/mL or higher 14.

Ongoing Monitoring

DEXA scanning every 1 to 2 years for the duration of treatment. Annual lipid panels, especially with nonsteroidal AIs. Hepatic function at baseline and as clinically indicated. For off-label use in men, monitoring should include serum estradiol every 3 to 6 months (target range 20 to 35 pg/mL), testosterone, hematocrit, and lipids 10.

Fracture Risk Assessment

FRAX score calculation at baseline helps guide the decision to initiate bone-protective therapy concurrently. Patients with a 10-year major osteoporotic fracture risk exceeding 20% or a hip fracture risk exceeding 3% warrant pharmacologic intervention per the ASCO Bone Health Guideline 7.

Special Populations

Premenopausal Women

AIs are contraindicated as monotherapy in premenopausal women because the hypothalamic-pituitary-ovarian axis compensates for estrogen suppression by increasing gonadotropin release, which stimulates ovarian estrogen production. The SOFT/TEXT trials (combined N=5,738) demonstrated that exemestane plus OFS (GnRH agonist or oophorectomy) improved DFS in high-risk premenopausal patients compared with tamoxifen plus OFS (HR 0.72, 95% CI 0.60 to 0.85) 15.

Hepatic Impairment

Letrozole AUC is approximately doubled in patients with severe cirrhosis. Use the lowest effective dose or consider exemestane, which has a shorter half-life and may be cleared more predictably 2.

Male Patients on TRT

No AI carries an FDA-approved indication in men. Prescribers should document the clinical rationale (symptomatic gynecomastia, estradiol above target range) and monitor bone density if AI therapy extends beyond 12 months. Over-suppression of estradiol below 10 to 15 pg/mL in men is associated with adverse skeletal and metabolic outcomes 10.

Agent Selection: Choosing Among the Three AIs

No head-to-head trial has demonstrated a clear DFS advantage for one AI over another in the adjuvant setting. The MA.27 trial (N=7,576) compared exemestane with anastrozole and found no significant difference in event-free survival (HR 1.02, 95% CI 0.87 to 1.18) 16.

Practical considerations drive selection:

• Bone-density concerns: exemestane may be preferred due to its androgenic metabolite and neutral-to-favorable effect on bone markers.
• Lipid sensitivity: exemestane shows less adverse lipid impact than nonsteroidal AIs in cross-trial comparison.
• Drug interactions: patients on CYP3A4-heavy regimens may benefit from anastrozole, which has a broader metabolic pathway including glucuronidation.
• Switching after toxicity: moving from a nonsteroidal to steroidal AI (or the reverse) permits continued AI therapy in 40 to 70% of patients who discontinued the first agent for musculoskeletal symptoms 11.

For men on TRT, anastrozole is most commonly used due to the largest body of published male-specific data and its manageable dosing intervals (0.5 mg two to three times weekly) 9.

Prescribing Considerations

All three AIs are available as generics, making cost a minor differentiator. Anastrozole and letrozole are taken without regard to food. Exemestane must be taken with food to achieve adequate absorption.

Treatment duration for adjuvant breast cancer is 5 years as standard, with extension to 7 to 10 years for patients at high recurrence risk (node-positive, large tumor, high Ki-67). The AIM trial showed benefit for extended letrozole in node-positive patients (HR 0.61 for distant recurrence), though absolute benefits were small in low-risk disease 17.

Patients should receive structured education about expected musculoskeletal symptoms, the importance of weight-bearing exercise, calcium (1,200 mg/day) and vitamin D (800 to 1,000 IU/day) supplementation, and the timeline for symptom improvement. Early management of joint symptoms with exercise programs reduces AI discontinuation rates by approximately 20% based on the HOPE trial (N=121) 18.

The recommended starting estradiol check for men on AI therapy is 4 to 6 weeks after initiation, with dose titration targeting an estradiol of 20 to 35 pg/mL.